Universe Pharmaceuticals INC Menerima Notifikasi Nasdaq Mengenai Kekurangan Harga Tawaran Minimum

(SeaPRwire) –   Ji’an, Jiangxi, China, 01 November 2024 — Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the “Notification Letter”) from Nasdaq Stock Market LLC (“Nasdaq”) on October 25, 2024, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.

Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s ordinary shares for the 30 consecutive business days from September 13, 2024 to October 24, 2024, the Company no longer meets the minimum bid price requirement.

The Notification Letter does not impact the Company’s listing on the Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until April 23, 2025, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s ordinary shares must have a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by April 23, 2025, the Company may be eligible for additional time to regain compliance or may face delisting.

The Company’s business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its ordinary shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding ordinary shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

About Universe Pharmaceuticals INC

Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company’s products are sold in 30 provinces of China. For more information, visit the company’s website at .

Penyataan Berpandu ke Hadapan

Semua kenyataan selain kenyataan fakta sejarah dalam pengumuman ini adalah kenyataan berpandu ke hadapan. Kenyataan berpandu ke hadapan ini melibatkan risiko dan ketidakpastian yang diketahui dan tidak diketahui dan berdasarkan jangkaan dan unjuran semasa mengenai peristiwa masa depan dan trend kewangan yang diyakini oleh Syarikat mungkin memberi kesan kepada keadaan kewangan, hasil operasi, strategi perniagaan dan keperluan kewangannya. Pelabur boleh mengenal pasti kenyataan berpandu ke hadapan ini dengan perkataan atau frasa seperti “mungkin,” “akan,” “menjangkakan,” “meramalkan,” “bertujuan,” “menganggarkan,” “bermaksud,” “merancang,” “percaya,” “potensi,” “terus,” “mungkin” atau ungkapan serupa yang lain. Syarikat tidak bertanggungjawab untuk mengemas kini kenyataan berpandu ke hadapan untuk mencerminkan peristiwa atau keadaan yang berlaku kemudian, atau perubahan dalam jangkaannya, kecuali seperti yang mungkin dikehendaki oleh undang-undang. Walaupun Syarikat percaya bahawa jangkaan yang dinyatakan dalam kenyataan berpandu ke hadapan ini adalah munasabah, ia tidak dapat menjamin bahawa jangkaan tersebut akan terbukti tepat, dan Syarikat memberi amaran kepada pelabur bahawa hasil sebenar mungkin berbeza secara material daripada hasil yang dijangkakan dan menggalakkan pelabur untuk menyemak faktor lain yang mungkin memberi kesan kepada hasilnya. keputusan masa depannya dalam pernyataan pendaftaran Syarikat dan dalam pemfailannya yang lain dengan Suruhanjaya Sekuriti dan Bursa Amerika Syarikat.

Hubungi:

Ms. Lin Yang,
Ketua Pegawai Kewangan Universe Pharmaceuticals INC